ATAI Life Sciences
ATAI
About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Employees: 54
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
229% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 7
115% more capital invested
Capital invested by funds: $29.7M [Q1] → $63.9M (+$34.2M) [Q2]
50% more call options, than puts
Call options by funds: $1.46M | Put options by funds: $971K
18% more funds holding
Funds holding: 79 [Q1] → 93 (+14) [Q2]
3.52% more ownership
Funds ownership: 11.04% [Q1] → 14.56% (+3.52%) [Q2]
14% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 22
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Patrick Trucchio
|
$15
|
Buy
Maintained
|
30 Jul 2025 |
|
Oppenheimer
Jay Olson
|
$14
|
Outperform
Initiated
|
29 Jul 2025 |
|
Canaccord Genuity
Sumant Kulkarni
|
$11
|
Buy
Maintained
|
28 Jul 2025 |
Financial journalist opinion
Based on 4 articles about ATAI published over the past 30 days
